This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Polypeptide N-acetylgalactos­aminyltransferase (GALNT; GalNac-T)

Patient sample, cell culture and mouse studies suggest inhibiting GALNT could help treat cancer. Addition of N-acetylgalactosamine to proteins by GALNT has previously been shown to correlate with metastatic potential. In human breast cancer tissue arrays, levels of proteins modified by N-acetylgalactosamine were 4.7-fold higher in malignant tissue than in normal or benign tissue tumor cores, with 70% of GALNT from highly expressing tissue localized to the endoplasmic reticulum (ER). In mouse xenograft models of metastatic lung cancer, injection of cells expressing a lectin that binds to N-acetylgalactosamine increased survival and decreased metastasis compared with injection of cells not expressing the lectin. Next steps include identifying substrates for GALNT in the ER.

SciBX 6(32); doi:10.1038/scibx.2013.855
Published online Aug. 22, 2013

Patent and licensing status undisclosed

Gill, D.J. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 2, 2013;
doi:10.1073/pnas.1305269110
Contact: Frederic A. Bard, Institute of Molecular and Cell Biology, Proteos, Singapore
e-mail:
fbard@imcb.a-star.edu.sg